Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun;153(6):1536-1539.
doi: 10.1016/j.jaci.2024.04.014.

Building and implementing a research infrastructure for eosinophilic gastrointestinal diseases

Glenn T Furuta  1 , Evan S Dellon  2 , Alex Straumann  3 , Nimi Gonsalves  4 , Marc E Rothenberg  5 , Ikuo Hirano  4
Affiliations
Editorial

Building and implementing a research infrastructure for eosinophilic gastrointestinal diseases

Glenn T Furuta et al. J Allergy Clin Immunol. 2024 Jun.
No abstract available

Keywords: CEGIR; Eosinophilic esophagitis; eosinophilic colitis; eosinophilic enteritis; eosinophilic gastritis; eosinophilic gastroenteritis; eosinophilic gastrointestinal diseases; eosinophilic oesophagitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement Disclosure of potential conflict of interest: G. T. Furuta serves as chief medical officer for EnteroTrack LLC; in addition, he has received research funding from Arena/Pfizer and the National Institutes of Health and consulted for Takeda, Regeneron Sanofi, and Bristol-Meyers Squibb. E. S. Dellon is a consultant for Abbott, AbbVie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, and Upstream Bio; in addition, he has received research funding from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Eupraxia, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, and Shire/Takeda, as well as educational grants from Allakos, Aqilion, Holoclara, and Invea. N. Gonsalaves is a consultant for AstraZeneca, Allakos, BMS, and Sanofi-Regeneron and has received speaking fees from Sanofi-Regeneron. A. Straumann has consulting contracts with AstraZeneca, BMS, Calypso, EsoCap, Falk Pharma, GSK, and Sanofi. M. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nexstone One, Santa Ana Bio, EnZen Therapeutics, Bristol-Myers Squibb, AstraZeneca, Pfizer, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first 9 of the aforementioned companies listed, as well as royalties from Teva Pharmaceuticals (for reslizumab), the Mapi Research Trust (for the Pediatric Eosiniphilic Esophagitis Symptom Score, version 2), and UpToDate. M. E. Rothenberg is an inventor of patents owned by Cincinnati Children’s Hospital. I. Hirano is a consultant for Ellodi/Adare, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos/Bristol-Myers Squibb, Esocap, Nextsone, Parexel/Calyx, Phathom, Regeneron/Sanofi, Shire/Takeda, and Phathom; in addition, he has received grant and/or research support from Pfizer/Arena, Celldex, Ellodi/Adare, Allakos, AstraZeneca, Celgene/Receptos/Bristol-Myers Squibb, Sanofi/Regeneron, and Shire/Takeda and speaker fees from Sanofi and Regeneron.

Figures

FIG 1.
FIG 1.
Key elements for building and implementing a research infrastructure for EGID. ESPGHAN, European Society for Paediatric Gastroenterology, Hepatology, and Nutrition; GERD, gastroesophageal reflux disease; GWAS, genome-wide association study.
See this image and copyright information in PMC

References

    1. Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vögtlin J. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr 1994;124:1419–29. - PubMed
    1. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001;107:83–90. - PMC - PubMed
    1. Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Lancet Gastroenterol Hepatol 2018;3:477–88. - PMC - PubMed
    1. Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology 2018;155:1022–33. - PMC - PubMed
    1. Hirano I, Collins MH, King E, Sun Q, Chehade M, Abonia JP, et al. Prospective endoscopic activity assessment for eosinophilic gastritis in a multisite cohort. Am J Gastroenterol 2022. Mar 1;117:413–23. - PMC - PubMed

Publication types

Supplementary concepts